Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants David Krempa - Vice President of Business Development Sean Brynjelsen - Chief Executive Officer Paul Stickler - Senior Vice President of Sales & Marketing Conference Call Participants Andrew D'silva - B.Riley FBR Operator Good afternoon and welcome to the Eton Pharmaceuticals Third Quarter 2020 Financial and Operating Results Conference Call. At this time, all participants are in a lis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in it ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants David Krempa – Vice President of Business Development Sean Brynjelsen – Chief Executive Officer Paul Stickler – Senior Vice President of Sales and Marketing Wilson Troutman – Chief Financial Officer Conference Call Participants Ram Selvaraju – H.C. Wainwright Andrew D’silva – B.Riley FBR Brooks O'Neil – Lake Street Capital Operator Good afternoon, and welcome to Eton Pharmaceuticals Seco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its cha ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants David Krempa - VP, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Paul Stickler - Senior Vice President of Sales and Marketing Conference Call Participants Andrew D'silva - B.Riley FBR Edward Marks - H.C. Wainwright Frank Takkinen - Lake Street Capital Markets Operator Good afternoon, and welcome to the Eton Pharmaceuticals First Qua ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its ch ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2019 Earnings Conference Call March 5, 2020 4:30 PM ET Company Participants David Krempa - VP, Business Development Sean Brynjelsen - President, CEO & Director Wilson Troutman - CFO, Treasurer & Secretary Conference Call Participants Andrew D'Silva - B. Riley FBR, Inc. Raghuram Selvaraju - H.C. Wainwright & Co. Frank Takkinen - Lake Street Capital Markets Michael Brcic - National Securities Corporation Keith Gil - Carter, Terry & Company Operator Good afternoon, a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------|-----------------------------------------------------| | FOR THE TRANSITION PERIOD F ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2019 Earnings Conference Call November 14, 2019 4:30 PM ET Company Participants David Krempa - Vice President, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Conference Call Participants Andrew D’Silva - B. Riley FBR Edward Marks - H.C. Wainwright Frank Takkinen - Lake Street Capital Operator Good afternoon and welcome to the Eton Pharmaceuticals Third Quarter 2019 Financial and Operating Results Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in it ...